STOCK TITAN

Aptevo Therapeutics (APVO) Stock News

APVO NASDAQ

Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.

Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.

Rhea-AI Summary

Aptevo Therapeutics (NASDAQ:APVO) reported third-quarter financial results and clinical progress for mipletamig in frontline acute myeloid leukemia, a blood cancer. Net loss narrowed to $6.5 million from $7.5 million a year earlier. Cash fell to $8.3 million at September 30, 2026, from $9.8 million at June 30.

Among 14 evaluable patients with TP53-mutated disease receiving mipletamig with venetoclax and azacitidine, 11 achieved complete remission or complete remission with incomplete blood-count recovery. Separately, ten of 47 evaluable frontline patients receiving the combination proceeded to stem cell transplantation. Aptevo reported fewer infusion-related reactions after priming-dose changes and targets RAINIER Phase 1b completion by year-end 2026, with regulatory interaction planned for first-half 2027.

An August financing raised approximately $4.5 million gross, or $4.1 million net, through warrant exercises and a private placement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.66%
Tags
-
Rhea-AI Summary

Aptevo Therapeutics (NASDAQ:APVO) closed a warrant exercise transaction generating approximately $3.0 million in gross proceeds before placement agent fees and expenses.

Holders agreed to exercise existing warrants for up to 2,777,778 common shares at a reduced price of $1.08 per share. In exchange, Aptevo will issue new warrants to purchase up to 13,888,890 common shares, also at $1.08 per share. The new warrants become exercisable on or after required stockholder approval and expire five years after their initial exercise date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.00%
Tags
none
-
Rhea-AI Summary

Aptevo Therapeutics (APVO) entered warrant exercise agreements expected to generate approximately $3.0 million in gross proceeds before fees and expenses.

Holders agreed to exercise existing warrants for up to 2,777,778 shares at a reduced price of $1.08 per share. In exchange, Aptevo will issue new warrants for up to 13,888,890 shares, also exercisable at $1.08 per share. These new warrants require stockholder approval before exercise and expire five years after their initial exercise date. The company expects closing on or about November 12, 2026, and intends to use net proceeds for working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.63%
Tags
none
Rhea-AI Summary

Aptevo Therapeutics (APVO) presented preclinical findings for three experimental solid-tumor immunotherapies at the SITC annual meeting on November 7, 2026. APVO451 and APVO452 demonstrated tumor-cell killing and T-cell activation under conditions that suppress immune responses. Both combine CD40 activation, which helps initiate immune responses, with T-cell engagement, which directs immune cells to kill cancer.

APVO711 demonstrated the ability to combine CD40 activation with PD-L1 checkpoint blockade, a mechanism intended to counter immune suppression. Aptevo views the laboratory findings as support for continued development of its solid-tumor portfolio. The molecules are designed to concentrate immune activation within tumors; the company aims to limit unwanted effects elsewhere in the body.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.87%
Tags
none
-
Rhea-AI Summary

Aptevo Therapeutics (APVO) reported fewer infusion-related reactions with mipletamig after refining the initial dosing regimen in its ongoing RAINIER study. The study evaluates mipletamig with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Aptevo described the reduction as substantial and reported favorable findings for cytokine release syndrome, a potentially serious inflammatory reaction.

Previously reported findings included remission responses in TP53-mutated AML and patients advancing to stem cell transplantation. The dosing findings do not establish improved efficacy or treatment persistence. Aptevo expects to complete the current study by year-end 2026, conduct regulatory interactions and initiate Phase 2 development in 2027. Mipletamig data will be presented at the American Society of Hematology meeting on December 12–15, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.30%
Tags
-
Rhea-AI Summary

Aptevo Therapeutics (APVO) reported that 21% of evaluable frontline acute myeloid leukemia patients advanced to stem cell transplant after mipletamig combination treatment.

Ten of 47 patients treated with mipletamig, venetoclax and azacitidine proceeded to donor stem cell transplantation, a potentially curative option. Nine were from the ongoing Phase 1b RAINIER trial and one from a completed dose expansion trial. These patients were initially considered unfit for intensive induction chemotherapy. Comparisons with historical venetoclax and azacitidine results are limited by differences in populations, study design and follow-up.

RAINIER is a Phase 1b/2 study whose current stage evaluates mipletamig dosing. Aptevo expects to complete that work by year-end 2026 and discuss next steps with regulators in the first half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.83%
Tags
none
Rhea-AI Summary

Aptevo Therapeutics (APVO) will present its multispecific platform at the SITC Annual Meeting, held November 4-8, 2026, in Phoenix, Arizona.

The presentation will cover its CD40-directed portfolio and its approach to combining innate and adaptive immunity, two arms of the immune system, within tumors. Aptevo says its molecules are designed to localize immune activation to tumors while seeking to limit activation elsewhere in the body. Michelle Nelson, PhD, and colleagues will present abstract 1060 at the Phoenix Convention Center. A copy will be available on Aptevo's Publications webpage after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Aptevo Therapeutics (APVO) is optimizing trispecific cancer-drug candidates for scalable manufacturing and expects APVO451 to enter IND-enabling studies in 1H2027.

The manufacturing work is intended to make the candidates reliably and consistently before human testing. Investigational New Drug (IND)-enabling studies are preparatory steps before that testing. The trispecific approach aims to combine three functions in one molecule: recognizing cancer, activating an immune response and helping overcome cancer defenses. Aptevo says its manufacturing capabilities may also support additional candidates from its ADAPTIR-FLEX platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
-
Rhea-AI Summary

Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate for its mipletamig triplet regimen in evaluable frontline TP53‑mutated acute myeloid leukemia (AML) patients. Of 14 patients treated with mipletamig plus venetoclax and azacitidine, 13 derived clinical benefit and 11 (79%) achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi).

The 79% CR/CRi rate compares with a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment‑naïve TP53‑mutated AML with poor‑risk cytogenetics. The ongoing RAINIER Phase 1b/2 trial is in dose optimization and is expected to complete this phase by year‑end, with regulatory interaction planned in 1H27. Mipletamig, Aptevo’s lead wholly owned bispecific candidate, has orphan drug designation for AML and is designed to target CD123‑expressing leukemic cells while aiming to limit cytokine release syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.23%
Tags
none
Rhea-AI Summary

Aptevo Therapeutics (NASDAQ: APVO) reported its 2Q26 business update, emphasizing clinical progress of lead candidate mipletamig in frontline acute myeloid leukemia (AML), non-dilutive funding for trispecific candidate APVO451, and expansion into radiopharmaceuticals through a 50/50 collaboration with Niowave.

In the Phase 1b/2 RAINIER trial, mipletamig plus venetoclax and azacitidine showed an 87% clinical benefit rate and 81% remission rate across 31 evaluable unfit frontline AML patients, with 55% of CR/CRi patients reaching MRD-negative status and six patients proceeding to allogeneic transplant. Aptevo received a $1.5 million non-dilutive grant to support APVO451 IND-enabling work and targets development candidate selection by year-end 2026. The Niowave collaboration covers up to three radiopharmaceutical programs and includes an equity investment giving Niowave an initial 7.9% ownership, potentially rising to 19.99%. Aptevo reported $9.8 million in cash and cash equivalents as of June 30, 2026, and raised $0.6 million via its SEPA facility during the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.53%
Tags

FAQ

What is the current stock price of Aptevo Therapeutics (APVO)?

Aptevo Therapeutics (APVO) last closed at $0.4041.

What is the market cap of Aptevo Therapeutics (APVO)?

The market cap of Aptevo Therapeutics (APVO) is approximately $854.0K.